clinical trial · NCT06801223
A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)
brief summary
The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate pediatric dosing regimens for patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections
started
Oct 30, 2026
primary completion
May 5, 2028
completion
May 20, 2028
last updated
Mar 3, 2026
official title
A Multicenter, Open-label, Phase 1b Study to Assess the Pharmacokinetics, Safety, and Tolerability of Sulbactam-Durlobactam in Hospitalized Pediatric Patients From Birth to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Acinetobacter Baumannii-calcoaceticus Complex Infection
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol